Processa Pharmaceuticals (PCSA) Price to Book (2014 - 2026)

Processa Pharmaceuticals (PCSA) has reported Price to Book for 13 consecutive years, with 16.9 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 3337.05% year-over-year to 16.9; the trailing twelve-month figure through Jun 2026 stood at 16.9 (down 3337.05% YoY), and the FY2025 full-year result was 0.68, down 57.61% from the prior year.
• Price to Book slipped to 16.9 in Q2 2026 per PCSA's latest filing, from 2.67 in the prior quarter.
• Across five years, Price to Book topped out at 2.67 in Q1 2026 and bottomed at 16.9 in Q2 2026.
• Historically, Price to Book has averaged 0.45 across 5 years, with a median of 1.27 in 2023.
• The widest YoY moves for Price to Book: up 166.76% in 2026, down 3337.05% in 2026.
• Over 5 years, Price to Book stood at 2.36 in 2022, then retreated by 26.86% to 1.73 in 2023, then slipped by 7.66% to 1.59 in 2024, then sank by 57.61% to 0.68 in 2025, then slumped by 2599.82% to 16.9 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 16.9, 2.67, and 0.68 for Q2 2026, Q1 2026, and Q4 2025 respectively.